RAVICTI 1.1 g/ml oral liquid
APHP230834
Phase 2 small_molecule active
Quick answer
RAVICTI 1.1 g/ml oral liquid for Pyruvate dehydrogenase deficiency is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- Pyruvate dehydrogenase deficiency
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active